A Dose Of Reality for Shareholders I start the morning by quoting VP Mathew Pfeffer on the Amphastar deal, We would not enter into an agreement unless we are confident we will be able to pay, and able to use the insulin. Agreement 2015-2019, 120 Mil Euro, which is about 30 Mil plus a year, starting 2015. The ER this year is later than usual. It is in fact the latest. Why, because they want to finalize all of the lose ends. No reason to release ER unless they have something worth sharing with us and its definitely not we lost money last quarter because we dont have anything that generate revenue. Deal with Amphastar was on 08/04/2014 Tuesday afternoon, with Monday ER after hour, that is exactly 4 business days, the maximum time SEC allow that you must inform the public of any major news affecting the company. This is very important because you have to ask yourself, Supply Agreement signed first, or Partnership sign first. My guess, they signed at the same time. No BP would enter an agreement with Mannkind not knowing how much they will pay. And one of main point is having a reliable supply of products. This supply agreement ensure that. It removes all of the uncertainty regarding products availability. Supply Chain Manager Job posting for mannkind on 08/07/2014. Responsibility involve with commercial partners. It is not posted on the website because they dont want to tip of. Linkedin is the key. Everythings like little puzzle that will come together on Monday. On Saturday, the websites. They were taking the site offline to update the website. Both Mannkindcorp and Mannkindtechnologies were down, but not AfrezzaREMS was online. On AfrezzaREMS it will list their post marketing strategy to get this off toward commercialization. Good luck to all of the long holders. Bad luck to all of the shorts. Monday is the day. I feel very confident riding with with AI, a proven leader with great track records. My guess is that this involves multiple partners, international and domestic. Merck seems to be the leading contender with the Amphastars connection. They were previouss owner of the insulin plant that currently own by Amphastar. AstraZeneca is not so far behind with over 100 diabetic sales rep open, and a Global Marketing Director in Diabetes with responsibility is to launch a new novel diabetic product. Congrats on a JOB well done by Mannkind Corporations. Congrats to all shareholders to stick with the company. Congrats to all of the diabetic patients who all of this efforts is all about it. Changing lives, Improving Lives one at a time.
Posted on: Sun, 10 Aug 2014 14:35:03 +0000
Trending Topics
Recently Viewed Topics
© 2015